NTRK1 and cancer: The ability of 45 to selectively inhibit the Trk pathway could indicate that it is essentially free of side-effects, which are generally related to off-target kinases inhibition, therefore representing a safer approach to treat pain, inflammation, cancer and skin diseases [89].